Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 4, 2025

FDA clears Epicrispr’s application for FSHD treatment

The US Food and Drug Administration (FDA) has granted clearance for an investigational new drug (IND) application of Epicrispr Biotechnologies’ EPI-321, intended for treating genetic neuromuscular condition, facioscapulohumeral muscular dystrophy (FSHD).

Plans are underway to commence the global Phase I/II trial this year. Credit: Lucas Vasques on Unsplash.